The FATE chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the FATE chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The FATE stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View FATE Detailed Price Forecast - CNN Money | View FATE Detailed Summary - Google Finance | ||
View FATE Detailed Summary - Yahoo! Finance | View FATE Stock Research & Analysis - Zacks.com |
View FATE Trends & Analysis - Trade-Ideas | View FATE Major Holders - Barrons | ||
View FATE Call Transcripts - NASDAQ | View FATE Breaking News & Analysis - Seeking Alpha | ||
View FATE Annual Report - CompanySpotlight.com | View FATE OTC Short Report - OTCShortReport.com | ||
View FATE Fundamentals - TradeKing | View FATE SEC Filings - Bar Chart | ||
View Historical Prices for FATE - The WSJ | View Performance/Total Return for FATE - Morningstar | ||
View the Analyst Estimates for FATE - MarketWatch | View the Earnings History for FATE - CNBC | ||
View the FATE Earnings - StockMarketWatch | View FATE Buy or Sell Recommendations - MacroAxis | ||
View the FATE Bullish Patterns - American Bulls | View FATE Short Pain Metrics - ShortPainBot.com |
View FATE Stock Mentions - StockTwits | View FATE Stock Mentions - PennyStockTweets | ||
View FATE Stock Mentions - Twitter | View FATE Investment Forum News - Investor Hub | ||
View FATE Stock Mentions - Yahoo! Message Board | View FATE Stock Mentions - Seeking Alpha |
View Insider Transactions for FATE - SECform4.com | View Insider Transactions for FATE - Insider Cow | ||
View FATE Major Holdings Summary - CNBC | View Insider Disclosure for FATE - OTC Markets | ||
View Insider Transactions for FATE - Yahoo! Finance | View Institutional Holdings for FATE - NASDAQ |
View FATE Stock Insight & Charts - FinViz.com | View FATE Investment Charts - StockCharts.com | ||
View FATE Stock Overview & Charts - BarChart | View FATE User Generated Charts - Trading View |
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Posted on Monday April 22, 2024
Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory B-cell Malignancies to be Highlighted Patient Enrollment Initiated in Phase 1 Study of FT819 Off-the-shelf, CD19-targeted, iPSC-derived CAR T-cell Therapy for Systemic Lupus Erythematosus SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage bio
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
Posted on Friday April 05, 2024
Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
Posted on Wednesday April 03, 2024
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 2:15 PM ET. A live webcast
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Posted on Tuesday April 02, 2024
SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that on April 1, 2024 the Company granted restricted stock units (RSUs) representing 6,400 shares of its common stock to one newly-hired non-executive employee. The grant was approved